Table 2.

Mean ± SEM Whole Blood Concentrations of rhTNF (ng/ml) Following Infusion with Various Dose Levels of CYT-6091

Time (min)	Dose Administered (μg/m2)
	50	100	150	200	250	300	400	500	600
5	7.7 ± 0.1	17.2 ± 2.6	25.2 ± 1.3	47.6 ± 5.8	58.2 ± 16.4	62.6 ± 12.1	85.1 ± 11.9	106.7 ± 9.7	154.7 ± 34.7
15	5.2 ± 0.7	10.1 ± 1.5	16.5 ± 1.0	34.2 ± 5.6	43.8 ± 9.7	48.1 ± 13.6	74.9 ± 13.4	73.8 ± 15.8	147.5 ± 22.8
30	4.0 ± 0.6	6.8 ± 1.0	11.4 ± 1.9	25.9 ± 6.9	24.4 ± 4.8	33.3 ± 9.8	58.4 ± 12.2	60.0 ± 16.2	109.2 ± 16.1
60	2.5 ± 0.4	3.5 ± 0.3	6.5 ± 1.2	15.5 ± 4.7	21.7 ± 2.8	21.3 ± 6.7	46.5 ± 4.6	43.3 ± 13.3	90.2 ± 12.7
120	1.3 ± 0.3	1.7 ± 0.1	3.2 ± 0.7	8.4 ± 2.9	10.9 ± 1.5	10.9 ± 4.0	21.7 ± 4.5	24.6 ± 8.3	47.2 ± 3.4
180	0.9 ± 0.2	1.1 ± 0.1	1.8 ± 0.4	4.6 ± 1.3	4.7 ± 0.6	4.3 ± 1.4	11.8 ± 3.8	12.2 ± 3.8	24.0 ± 1.8
240	0.6 ± 0.1	0.7 ± 0.1	1.3 ± 0.3	3.1 ± 0.9	2.6 ± 0.4	2.4 ± 0.8	6.1 ± 1.6	8.9 ± 3.0	12.3 ± 1.1
480	0.2 ± 0.1	0.2 ± 0.0	0.4 ± 0.2	1.0 ± 0.2	0.8 ± 0.0	0.8 ± 0.4	1.6 ± 0.5	2.6 ± 0.6	2.6 ± 0.0
1440	BDL	BDL	BDL	BDL	BDL	BDL	0.3 ± 0.1	1.2 ± 0.1	0.6 ± 0.0

BDL= Below the limit of detection.
Analysis (Mean ± S.D.) of the Pharmacokinetic Parameters of CYT-6091 in Man
Dose of CYT-6091 (μg/m2)	Total Dose (μg)	Cmax (ng/mL)	Terminal Half Life (min)	AUC (min*ng/mL)	Volume of Distribution (mL)	Clearance (mL/min)
50	90 ± 5	7.7 ± 0.2	120.7 ± 19.6	611 ± 192	18686 ± 2988	155 ± 40
100	202 ± 33	17.2 ± 4.6	131.3 ± 21.0	977 ± 64	24064 ± 8308	209 ± 48
150	270 ± 49	25.2 ± 2.3	127.0 ± 34.4	1575 ± 412	18641 ± 2845	177 ± 67
200	314 ± 7	47.7 ± 9.9	146.3 ± 22.2	3789 ± 1465	12063 ± 5174	90 ± 28
250	410 ± 62	58.2 ± 16.4	112.7 ± 27.2	3888 ± 890	11355 ± 3536	107 ± 23
300	563 ± 45	62.6 ± 21.0	113.0 ± 46.2	4403 ± 2223	13241 ± 4637	159 ± 96
400	785 ± 148	85.1 ± 20.7	266.0 ± 79.0	9297 ± 3845	16265 ± 9021	97 ± 51
500	823 ± 153	106.7 ± 16.7	371.1 ± 133	11206 ± 4359	31248 ± 27137	84 ± 53
600	1208 ± 214	154.7 ± 34.7	160.5 ± 52.0	17730 ± 2928	10865 ± 5666	71 ± 24